World Journal of Surgery

, Volume 29, Issue 9, pp 1172–1175

Detection of Lymph Node Micrometastases and Isolated Tumor Cells in Sentinel and Nonsentinel Lymph Nodes of Colon Cancer Patients

  • Andreas Bembenek
  • Ulrike Schneider
  • Stephan Gretschel
  • Joerg Fischer
  • Peter M. Schlag


About 20% to 30% of colon cancer patients classified as node negative by routine hematoxylin-eosin (H&E) staining are found to have micrometastases (MM) or isolated tumor cells (ITC) in sentinel lymph nodes (SLNs) if analyzed by step sections and immunohistochemistry (IHC). Whether SLNs are in this respect representative for all lymph nodes was addressed in this study. SLNs were identified using the intraoperative blue dye detection technique. If all lymph nodes (SLNs and non-SLNs) of a patient were negative by routine H&E staining, they were step-sectioned and analyzed by IHC using pancytokeratin antibodies. We identified at least one SLN in 47 of the 55 patients (85%) and examined a median of 26 lymph nodes per patient (range 10–59). By routine H&E staining, 14 of the 47 patients showed lymph node metastases (30%); the remaining 33 were classified as node-negative. In this group (33 patients), 1011 lymph nodes were analyzed by step sections and IHC: 14 of 70 SLNs. (20%) but only 37 of 941 non-SLNs (4%) had MM/ITC (p < 0.001). Furthermore, 13 of the 33 H&E-negative patients were found to have MM/ITC (39%). In 11 of the 13 patients, MM/ITC were identified in both SLNs and non-SLNs in 1 patient in the SLN only, and in 1 patient in a non-SLN only (sensitivity for the identification of MM/ITC: 92%; negative predictive value: 95%). The SLN biopsy is a valid tool to detect, as well as exclude, the presence of MM/ITC in colon cancer patients. Our results may be of prognostic relevance and influence patient stratification for adjuvant therapy trials.


  1. 1.
    Greenson JK, Craig EI, Rice R, et al. Identification of occult micrometastases in pericolic lymph nodes of Dukes’ B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Cancer 1994;73:563–569PubMedGoogle Scholar
  2. 2.
    Clarke G, Ryan E, Crowe J, et al. Immunohistochemical detection of mutant p53 protein in regional lymph nodes is associated with adverse outcome in stage 2 colorectal cancer. Eur. J .Histochem. 1999;43:311–316PubMedGoogle Scholar
  3. 3.
    Broll R, Schauer V, Schimmelpenning H, et al. Prognostic relevance of occult tumor cells in lymph nodes of colorectal carcinomas. Dis. Colon Rectum 1997;401:1465–1471CrossRefGoogle Scholar
  4. 4.
    Noura S, Yamamoto Y, Ohnishi T, et al. Comparative detection of lymph node micrometastases of stage 2 colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry. J. Clin. Oncol. 2002;20:4232–4241CrossRefPubMedGoogle Scholar
  5. 5.
    Rosenberg R, Friederichs J, Gertler R, et al. Prognostic evaluation and review of immunohistochemically detected disseminated tumor cells in peritumoral lymph nodes of patients with pN0 colorectal cancer. Int. J. Colorectal Dis. 2004;19:430–437CrossRefPubMedGoogle Scholar
  6. 6.
    Schulze T, Bembenek A, Schlag PM. Sentinel lymph node biopsy progress in surgical treatment of cancer. Langenbeck’s Arch. Surg. 2004;389:532–550CrossRefGoogle Scholar
  7. 7.
    Schlag PM, Bembenek A, Schulze T. Sentinel node biopsy in gastrointestinal-tract cancer. Eur. J. Cancer 2004;40:2022–2032CrossRefPubMedGoogle Scholar
  8. 8.
    Wood TF, Nora DT, Morton DL, et al. One hundred consecutive cases of sentinel lymph node mapping in early colorectal carcinoma: detection of missed micrometastases. J. Gastrointest. Surg. 2002;6:322–330CrossRefPubMedGoogle Scholar
  9. 9.
    Bilchik AJ, Saha S, Wiese D, et al. Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter trial. J. Clin. Oncol. 2001;19:1128–1136PubMedGoogle Scholar
  10. 10.
    Trocha SD, Nora DT, Saha SS, et al. Combination probe and dye-directed lymphatic mapping detects micrometastases in early colorectal cancer. J. Gastrointest. Surg. 2003;7:340–346CrossRefPubMedGoogle Scholar
  11. 11.
    Bilchik AJ, Nora DT, Sobin LH, et al. Effect of lymphatic mapping on the new tumor-node-metastasis classification for colorectal cancer. J. Clin. Oncol. 2003;21:668–672CrossRefPubMedGoogle Scholar
  12. 12.
    Bembenek A, Schneider U, Gretschel S, et al. Optimization of staging in colon cancer using sentinel lymph node biopsy. Chirurg 2005;75:761–766Google Scholar
  13. 13.
    Paramo JC, Summerall J, Poppiti R, et al. Validation of sentinel node mapping in patients with colon cancer. Ann. Surg. Oncol. 2002;9:550–554CrossRefPubMedGoogle Scholar
  14. 14.
    Bell SW, Mourra N, Flejou JF, et al. Ex vivo sentinel lymph node mapping in colorectal cancer. Dis. Colon Rectum 2005;48:74–79CrossRefPubMedGoogle Scholar
  15. 15.
    Meyer JS. Sentinel lymph node biopsy: strategies for pathologic examination of the specimen. J. Surg. Oncol. 2001;69:212–218CrossRefGoogle Scholar
  16. 16.
    Hermanek P, Hutter RV, Sobin LH, et al. International Union Against Cancer: classification of isolated tumor cells and micrometastasis. Cancer 1999;86:2668–2673CrossRefPubMedGoogle Scholar
  17. 17.
    Bertagnolli M, Miedema B, Redston M, et al. Sentinel node staging of resectable colon cancer: results of a multicenter study. Ann. Surg. 2004;240:624–630PubMedGoogle Scholar
  18. 18.
    Braat AE, Oosterhuis JW, Moll FC, et al. Successful sentinel node identification in colon carcinoma using Patentblue V. Eur. J. Surg. Oncol. 2004;30:633–637CrossRefPubMedGoogle Scholar
  19. 19.
    Saha S, Monson KM, Bilchik A, et al. Comparative analysis of nodal upstaging between colon and rectal cancers by sentinel lymph node mapping: a prospective trail. Dis. Colon Rectum 2004;47:1767–1772CrossRefPubMedGoogle Scholar
  20. 20.
    Read T, Fleshman JW, Caushaj PF. Sentinel lymph node mapping for adenocarcinoma of the colon does not improve staging accuracy. Dis. Colon Rectum 2005;48:80–85CrossRefPubMedGoogle Scholar
  21. 21.
    Johnson DS, Wong JH. The impact on nodal staging of lymphatic mapping in carcinoma of the colon and rectum. Semin. Oncol. 2004;31:403–408CrossRefPubMedGoogle Scholar
  22. 22.
    Turner RR, Nora DT, Trocha SD, et al. Colorectal carcinoma nodal staging: frequency and nature of cytokeratin-positive cells in sentinel and nonsentinel lymph nodes. Arch. Pathol. Lab. Med. 2003;127:673–679PubMedGoogle Scholar
  23. 23.
    Chu KU, Turner RR, Hansen NM, et al. Sentinel node metastasis in patients with breast carcinoma accurately predicts immunohistochemical detectable nonsentinel node metastasis. Ann. Surg. Oncol. 1999;6:756–761CrossRefPubMedGoogle Scholar
  24. 24.
    Chu KU, Turner RR, Hansen NM, et al. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann. Surg. 1999;229:536–541Google Scholar
  25. 25.
    Turner RR, Ollila DS, Krasne DL, et al. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann. Surg. 1997;226:271–278CrossRefPubMedGoogle Scholar
  26. 26.
    Diaz NM, Cox CE, Ebert M, et al. Benign mechanical transport of breast epithelial cells to sentinel lymph nodes. Am. J. Surg. Pathol. 2004;28:1641–1645PubMedGoogle Scholar
  27. 27.
    International Breast Cancer Study Group. Prognostic importance of occult axillary lymph ode micrometastases from breast cancers. Lancet 1990;335:1565–1568Google Scholar
  28. 28.
    Cote JR, Peterson HF, Chaiwun B, et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. Lancet 1999;354:896–900CrossRefPubMedGoogle Scholar
  29. 29.
    Greene FL, Balch CM, Fleming A, et al. AJCC Cancer Staging Manual; American Joint Committee on Cancer, 6th edition, Berlin, Springer-Verlag, 2002Google Scholar

Copyright information

© Société Internationale de Chirurgie 2005

Authors and Affiliations

  • Andreas Bembenek
    • 1
  • Ulrike Schneider
    • 2
  • Stephan Gretschel
    • 1
  • Joerg Fischer
    • 3
  • Peter M. Schlag
    • 1
  1. 1.Department of Surgery and Surgical Oncology Charité – University Medicine Berlin, Robert-Rössle Cancer CenterBerlinGermany
  2. 2.Department of PathologyCharité – University Medicine Berlin, Robert-Rössle Cancer CenterBerlinGermany
  3. 3.Data Processing and Statistics Charité – University Medicine Berlin, Robert-Rössle Cancer CenterBerlinGermany

Personalised recommendations